symbol MSB
会社名 Mesabi Trust (MESABI TRUST)
業種 鉄鋼   原材料・素材(Materials)
概要 メサビ・トラスト(Mesabi Trust)(同信託)はロイヤルティー・トラストである。同信託はメサビ鉄山東部のミネソタ州バビットに位置する鉄鉱山(Peter Mitchell Mine)から収益を挙げる。同信託は、信託財産を保護・保全するほか、費用と負債の支払い後(提供)で信託の承認保有者のために、収入・収益を収集・分配する。信託契約により、同信託が行うロイヤルティーと費用の支払い以外の事業活動は禁止される。同信託鉱物権益の借主・オペレーターはCliffs Natural Resources Inc (Cliffs)の子会社であるNorthshore Mining Corporation (NMC)。Cliffs Natural Resources Incは鉄鉱製品の生産者である。同信託はMesabi Iron Companyが所有していた全部の権利を保有する。  メサビ・トラストは、米国の信託会社。ミネソタ州セントルイス郡に広がる土地に位置するメサビ鉄山において二つのプロジェクト「Peters Lease」と「Cloquet Lease」の投資を手掛ける。Peters Lease Landsの所有者として20%の利子を取得するほか、隣接する非鉱物生産地の所有者として100%のリ―ス手数料を所有。  Mesabi Trust engages in the collection and distribution of royalties and payment of expenses and liabilities. It holds interest in Peter Mitchell iron mine located near Babbitt and in Silver Bay, Minnesota. The company was founded on July 18, 1961 and is headquartered in New York, NY.
本社所在地 c/o Deutsche Bank Trust Company Americas Trust_Agency Services 60 Wall Street 16th Floor New York NY 10005 USA
電話番号 +1 212-250-6519
設立年月日 22463
市場名 NYSE(ニューヨーク証券取引所)
EBITDA (百万ドル) 43.82784
時価総額 (百万ドル) 395.83070
売上高 (百万ドル) 45.17444
企業価値(EV) (百万ドル) 362.65384
当期純利益 (百万ドル) 43.82785
決算概要 BRIEF: For the nine months ended 31 October 2018 Mesabi Trust revenues increased 33% to $39.8M. Net income increased 33% to $38.8M. Revenues reflect Interest increase from $40K to $147K. Dividend per share increased from $1.98 to $2.55. Basic Earnings per Share excluding Extraordinary Items increased from $2.22 to $2.96.



   Mesoblast's (ASX:MSB) good COVID-19 news | Rask Media  2020/09/04 22:15:04 Rask Media
Mesoblast Limited (ASX:MSB) shares dropped 3% on Friday after announcing news relating to COVID-19 patients.
   Buy, hold, sell: Telstra, CSL, Mesoblast, Dacian Gold, EML Payments  2020/09/04 01:56:52 The Australian Financial Review
These stocks are the most searched-for on Livewire Markets – but are they a buy?
   The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO  2020/09/02 11:25:11 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) 10X Genomics Inc (NASDAQ: TXG ) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Catalent Inc (NYSE: CTLT ) Evogene Ltd (NASDAQ: EVGN ) (announced $10 million equity investment led by ARK Investment Management) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PPD Inc (NASDAQ: PPD ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 1) Acasti Pharma Inc (NASDAQ: ACST ) ADiTx Therapeutics Inc (NASDAQ: ADTX ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Entera Bio Ltd (NASDAQ: ENTX ) Freeline Therapeutics Holdings PLC (NASDAQ: FRLN ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Immatics NV (NASDAQ: IMTX ) NanoVibronix Inc (NASDAQ: NAOV ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Predictive Oncology Inc (NASDAQ: POAI ) Rockwell Medical Inc (NASDAQ: RMTI ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Stocks In Focus Mesoblast Gets Ethics Approval For Using Stem Cell Therapy In COVID-19 Patients In Australia Mesoblast (NASDAQ: MESO ) said it has received ethics approval to include Australian hospitals in the Phase 3 randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome.
   Mesoblast (ASX:MSB) receives ethics approval to treat Covid-19 patients  2020/09/02 01:41:00 Finance News Network
02 Sep 2020 - Mesoblast (ASX:MSB) today announced that it has received ethics approval to include Australian hospitals in the controlled trial of remestemcel-L Covid-19 patients with acute respiratory distress syndrome (ARDS).
   Mesoblast reports FY results (NASDAQ:MESO)  2020/08/27 06:06:05 Seeking Alpha
Mesoblast (NASDAQ:MESO): FY GAAP EPS of -$0.147. Revenue of $32.16M (+92.3% Y/Y) The company reported 32% increase in royalty revenue on Temcell HS. Inj. s

 関連キーワード  (鉄鋼 米国株 MESABI TRUST MSB )


 twitter  (公式ツイッターやCEOツイッターなど)